Trials / Completed
CompletedNCT00195585
Study Evaluating Isovorin in Colon Cancer
Post-Approved Phase III Study of 1-LV/5FU Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 650 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isovorin | |
| DRUG | UFT |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-09-19
- Last updated
- 2009-08-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00195585. Inclusion in this directory is not an endorsement.